ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CSBR vs PTHS // REVENUE GROWTH (YOY)

Champions Oncology Inc. (NASDAQ) VS. Pelthos Therapeutics Inc. (NYSE) • 15-METRIC TALLY: CSBR 5 — PTHS 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CSBR VS. PTHS) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CSBR PTHS SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 48.00% 76.30% -28.30 PTHS /gross-margins <GO>
Return on Invested Capital (ROIC) -26.90% -35.00% +8.10 CSBR /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -7.52% — — TIE /fcf-yield <GO>
Operating Margin -1.90% -60.00% +58.10 CSBR /operating-margins <GO>
Net Profit Margin 0.00% -60.00% +60.00 CSBR /net-margins <GO>
Revenue Growth (YoY) ACTIVE 4.40% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 0.20 0.00 TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 3/9 -1.00 PTHS /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 46.7 21.8 +24.87 CSBR /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $66.9M $63.3M $3.6M CSBR /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CSBR REV PTHS REV CSBR GROSS % PTHS GROSS % CSBR FCF PTHS FCF
FY 2025 $59.4M $16.8M 48.0% 76.3% -$5.0M -$22.7M
FY 2024 $56.9M $0 50.1% — $7.0M -$5.8M
FY 2023 $50.2M $0 — — -$6.1M -$981.0K
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CSBR // BETA —
PTHS // BETA —